143443-90-7|Ifetroban|CsnPharm

欢迎来到CSNpharm！产品仅用于科研！

400-920-2911 sales@csnpharm.cn

^NEW 新产品

登录 | 注册会员中心 0

您的位置 : 首页 / GPCR/G Protein / Prostaglandin Receptor / Ifetroban

CAS No.: 143443-90-7

Ifetroban Catalog No. CSN22113

Synonyms: BMS-180291;BMS 180291-02

Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

描述Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02216357	-	-	Completed	-	-
NCT03340675	Duchenne Muscular Dystrophy Ca... more >>rdiomyopathy Cardiomyopathy, Dilated Collapse <<	Phase 2	Not yet recruiting	December 2021	-
NCT02802228	Portal Hypertension ... more >> Liver Cirrhosis Collapse <<	Phase 2	Completed	-	United States, Florida ... more >> Tampa General Medical Group Tampa, Florida, United States, 33606 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Medical Center Richmond, Virginia, United States, 23114 Collapse <<

更多

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2700 mL
- 11.3499 mL
- 22.6998 mL
- 5 mM
- 0.4540 mL
- 2.2700 mL
- 4.5400 mL
- 10 mM
- 0.2270 mL
- 1.1350 mL
- 2.2700 mL

技术信息

CAS号	143443-90-7		储存条件	粉末液体 -20°C:3-6 月 -80°C:12月
分子式	C25H32N2O5		运输	蓝冰
分子量	440.53		别名	BMS-180291;BMS 180291-02

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02216357	-	-	Completed	-	-
NCT03340675	Duchenne Muscular Dystrophy Ca... more >>rdiomyopathy Cardiomyopathy, Dilated Collapse <<	Phase 2	Not yet recruiting	December 2021	-
NCT02802228	Portal Hypertension ... more >> Liver Cirrhosis Collapse <<	Phase 2	Completed	-	United States, Florida ... more >> Tampa General Medical Group Tampa, Florida, United States, 33606 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Medical Center Richmond, Virginia, United States, 23114 Collapse <<
NCT03694249	Anatomic Stage II Breast Cance... more >>r Anatomic Stage IIA Breast Cancer Anatomic Stage IIB Breast Cancer Anatomic Stage III Breast Cancer Anatomic Stage IIIA Breast Cancer Anatomic Stage IIIB Breast Cancer Anatomic Stage IIIC Breast Cancer Clinical Stage II Esophageal Adenocarcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma Clinical Stage II Gastric Cancer Clinical Stage II Gastroesophageal Junction Adenocarcinoma Clinical Stage IIA Esophageal Adenocarcinoma Clinical Stage IIA Gastric Cancer Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma Clinical Stage IIB Esophageal Adenocarcinoma Clinical Stage IIB Gastric Cancer Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma Clinical Stage III Esophageal Squamous Cell Carcinoma Clinical Stage III Gastric Cancer Clinical Stage III Gastroesophageal Junction Adenocarcinoma Distal Esophagus Squamous Cell Carcinoma Esophageal Carcinoma Estrogen Receptor Negative HER2/Neu Negative Limited Stage Small Cell Lung Carcinoma Malignant Solid Neoplasm Non-Small Cell Lung Carcinoma Pancreatic Adenocarcinoma Pathologic Stage II Esophageal Adenocarcinoma Pathologic Stage II Esophageal Squamous Cell Carcinoma Pathologic Stage II Gastric Cancer Pathologic Stage II Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIA Esophageal Adenocarcinoma Pathologic Stage IIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIA Gastric Cancer Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIB Esophageal Adenocarcinoma Pathologic Stage IIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIB Gastric Cancer Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Esophageal Adenocarcinoma Pathologic Stage III Esophageal Squamous Cell Carcinoma Pathologic Stage III Gastric Cancer Pathologic Stage III Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIA Esophageal Adenocarcinoma Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIIA Gastric Cancer Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIB Esophageal Adenocarcinoma Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIIB Gastric Cancer Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIC Gastric Cancer Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage II Gastric Cancer Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage III Gastric Cancer Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma Progesterone Receptor Negative Prognostic Stage II Breast Cancer Prognostic Stage IIA Breast Cancer Prognostic Stage IIB Breast Cancer Prognostic Stage III Breast Cancer Prognostic Stage IIIA Breast Cancer Prognostic Stage IIIB Breast Cancer Prognostic Stage IIIC Breast Cancer Stage I Pancreatic Cancer Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage II Lung Cancer Stage II Pancreatic Cancer Stage IIA Lung Cancer Stage IIA Pancreatic Cancer Stage IIB Lung Cancer Stage IIB Pancreatic Cancer Stage III Lung Cancer Stage IIIA Lung Cancer Stage IIIB Lung Cancer Stage IIIC Lung Cancer Triple-Negative Breast Carcinoma Collapse <<	Phase 2	Not yet recruiting	January 2023	United States, Tennessee ... more >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Vanderbilt-Ingram Service for Timely Access 800-811-8480 cip@vanderbilt.edu Principal Investigator: Ingrid Mayer, MD Collapse <<
NCT01436500	Hepatorenal Syndrome	Phase 2	Completed	-	United States, Arizona ... more >> Mayo Clinic - Arizona Phoenix, Arizona, United States, 85054 United States, California UCSD, Hillcrest Medical Center Hospital La Jolla, California, United States, 92093 UCSF (University of California-San Francisco) San Francisco, California, United States, 94143 United States, Georgia Emory University Hospital Atlanta, Georgia, United States, 30322 United States, Indiana Indiana University (Division of Gastroenterology/Hepatology) Indianapolis, Indiana, United States, 46202 United States, Michigan University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 United States, New York NYU Langone Medical Center New York, New York, United States, 10016 United States, Ohio The Ohio State University Columbus, Ohio, United States, 43210 United States, Texas Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Utah University of Utah Health Sciences Center Salt Lake City, Utah, United States, 84132 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 India MIDAS Multispeciality Hospital PVT LTD Nagpur, Maharashtra, India, 440010 Collapse <<
NCT02216357	Aspirin Exacerbated Respirator... more >>y Disease (AERD) Collapse <<	Phase 2	Completed	-	United States, California ... more >> Scripps Clinic San Diego, California, United States, 32130 United States, Kansas Kansas City Allergy and Asthma Associates, PA. Overland Park, Kansas, United States, 66210 United States, New York Allergy & Asthma Consultants of Rockland & Bergen West Nyack, New York, United States, 10994 Collapse <<
NCT03326063	Nasal Polyps ... more >>Asthma, Aspirin-Induced Aspirin-exacerbated Respiratory Disease Aspirin-Sensitive Asthma With Nasal Polyps Collapse <<	Phase 2	Recruiting	February 2021	United States, Massachusetts ... more >> Asthma Research Center, Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Meghan Le 617-732-8201 mle8@bwh.harvard.edu Collapse <<
NCT02682511	Scleroderma, Diffuse ... more >> Scleroderma, Systemic Scleroderma, Limited Sclerosis, Progressive Systemic Skin Diseases Connective Tissue Diseases Pathologic Processes Autoimmune Diseases Collapse <<	Phase 2	Recruiting	February 2020	United States, California ... more >> UCLA Recruiting Los Angeles, California, United States, 90095-1670 Contact: Nashla Barroso 310-825-9682 Principal Investigator: Suzanne Kafaja, MD United States, Florida New Life Medical Research Center, Inc. Recruiting Hialeah, Florida, United States, 33012 Contact: Barbara Diaz, BS 786-360-3750 diaz@newlifemedresearch.com Principal Investigator: Odalys P Frontela, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21224 Contact: Gwen Leatherman, RN, MS, CCRP 410-550-8582 Principal Investigator: Laura Hummer, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kaitlin Schalago 617-724-2792 Contact: Ana Fernandez 617-724-2792 Principal Investigator: Flavia Castelino, MD United States, New York Hospital for Special Surgery Recruiting New York, New York, United States, 10021 Contact: Alexandra Morquette 212-774-7194 Principal Investigator: Jessica Gordon, MD United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29403 Contact: Kelley Kajdasz 843-792-5290 Principal Investigator: Richard Silver, MD United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Rezzan Hekmat, MHS 615-875-8937 Principal Investigator: Evan Brittain, MD Collapse <<
NCT03028350	Asthma, Aspirin-Induced	Phase 2	Recruiting	December 2019	United States, California ... more >> Scripps Clinic - Carmel Valley Recruiting San Diego, California, United States, 92130 Contact: Nancy Giovanetty 858-764-3023 Principal Investigator: Andrew White, MD Stanford University Medical Center Recruiting Stanford, California, United States, 94305 Contact: Aakanksha Rathor, MD 408-872-2257 Principal Investigator: Peter Hwang, MD United States, Florida The Research Center Recruiting Hialeah, Florida, United States, 33013 Contact: Laine Batista 305-603-8844 Contact: Damian Beltran-Garces (305) 603-8844 United States, Kansas Kansas City Allergy and Asthma Associates, PA Recruiting Overland Park, Kansas, United States, 66210 Contact: James B Sterner, MD 913-338-1610 Contact: Andrea Bennington, CCRC 913-338-1610 United States, New York Montefiore Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Mydalyn Beronilla, MPH 929-263-3262 Principal Investigator: Elina Jerschow, MD United States, Ohio Clinical Research Trials , LLC Recruiting Canton, Ohio, United States, 44718 Contact: Nashat Gabrail, MD 330-492-3345 Contact: Hannah Crocker 330-492-3345 United States, Pennsylvania University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: John V Bosso, MD Contact: Laurel Doghramji, BSN 215-615-1643 United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Cindy Dorminy, MEd, LPN 615-936-8384 Principal Investigator: Rakesh Chandra, MD United States, Texas UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390-9035 Contact: Mary Martin 214-648-3626 Principal Investigator: David Khan, MD United States, Virginia University of Virginia Medical Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: B.J. Ferrebee Ghamandi, MHA 434-243-1558 Principal Investigator: Spencer Payne, MD Collapse <<
NCT01436500	-	-	Completed	-	-

总药量计算器 ✕

动物实验：给药剂量mg/kg 动物体重g 动物数量只每天给药次给药天

需要的总药量：mg

工作液计算器 ✕

动物实验：给药剂量mg/kg 动物体重g 给药体积μL

您需要配制的工作液浓度为：mg/mL

优势价格
快速发货
品质保证
技术支持

联系我们

sales@csnpharm.cn

官方电话：400-920-2911
二维码
微信公众号 CSN官网

dandb BBB norton fedex dhl ups 顺丰沪公网安备 31011002004927号，沪ICP备09052192号-6 危化品许可证:沪(杨)应急管危经许[2021]203479(QYS)

csnpharm版权所有2023，产品仅用于科研！